TopoGEN, Inc. Marks 25 Years as a Trusted Leader in Drug discovery R&D in cancer and antibiotics.

TopoGEN, Inc., a Colorado based life sciences company, is marking over 25 years of continuous operation as a specialized provider of research tools and contract services supporting cancer biology, genome surveillance, and drug discovery programs. Founded in the late 1990s, TopoGEN has built a global reputation for scientific rigor, reliability, and deep expertise in both prokaryotic and eukaryotic DNA topoisomerases and DNA damage response pathways. The company is strongly e-commerce based and has a global footprint with more than 15 distributors worldwide.

Unlike early stage startups, TopoGEN is a mature, revenue generating company with a long history of serving academic laboratories, biotechnology firms, and pharmaceutical organizations worldwide. Its products and technologies have been cited thousands of times in peer reviewed scientific publications, underscoring broad adoption and sustained impact across oncology, infectious disease, and genomic research.

TopoGEN is best known for its comprehensive portfolio of topoisomerase and gyrase enzymes, antibodies, DNA substrates/targets, biochemical assays, and cell based platforms, which are widely used to study mechanisms of action for anticancer and antimicrobial drugs. A cornerstone of the company's offerings is it's the new In vivo Complex of Enzyme (ICE) assay technology, which enables direct measurement of covalent topoisomerase-DNA complexes within cells. This approach provides uniquely cell context insight into drug action. An essential feature in drug discovery to validate that the drug in question will work in the clinic. Clearly a critical parameter for modern drug development.
In addition to reagents and kits, TopoGEN operates as a specialized contract research organization (CRO), supporting lead discovery, mechanism of action studies, resistance analysis, and translational research. The company's platforms have contributed to the development of novel anticancer agents, antibiotics, and therapies targeting both acute and chronic human diseases.
As precision oncology and DNA targeted therapeutics continue to expand, TopoGEN is strategically positioned for partnership, licensing, and acquisition discussions, offering a rare combination of long standing credibility, proprietary assay technologies, and a highly cited scientific footprint.

About the Founder
TopoGEN was founded by Dr. Mark T. Muller, Ph.D., a molecular genetics expert with decades of experience in DNA topology, genome stability, and drug mechanism research. Dr. Muller is a recognized authority in the topoisomerase field and has led TopoGEN since its inception, guiding its evolution into a globally respected resource for the life sciences community. For more information, visit www.topogen.com.

TopoGEN, Inc.
PO Box 1219
Buena Vista, CO 81211
Dr. Mark Muller, CEO
mark@topogen.com
Presscontact, soren@topogen.com

About TopoGEN, Inc.
TopoGEN, Inc. is an established life sciences company with over 25 years of operating history, built around proprietary technologies and deep expertise in DNA topology and genome stability. The company offers a differentiated portfolio of high‐value research products, cell‐based assay platforms, and specialized CRO services that support oncology and infectious disease drug development. With a globally distributed customer base, extensive peer‐reviewed validation, and recurring revenue streams, TopoGEN represents a scalable, de‐risked platform well suited for strategic partnership, licensing, or acquisition.

This release was published on openPR.